Related Experiment Video
Updated: Dec 21, 2025

06:51
Physical Activity Measurement in Children Accepting Table Tennis Training
Published on: July 27, 2022
2.3K
Physical activity in people with epilepsy: A systematic review
Emma C Johnson1,2, J Helen Cross1,2,3, Colin Reilly1,3
1Research Department, Young Epilepsy, Surrey, UK.
Epilepsia
|May 13, 2020
Summary
People with epilepsy (PWE) may engage in less physical activity (PA) than others. Interventions show promise for improving PA and quality of life, but more research is needed.
Area of Science:
- Neurology
- Exercise Science
- Public Health
Background:
- Physical activity (PA) levels in people with epilepsy (PWE) are not well understood compared to the general population.
- Factors influencing PA in PWE and the impact of interventions require systematic investigation.
Purpose of the Study:
- To systematically review studies comparing PA levels in PWE versus controls.
- To identify factors associated with PA in PWE.
- To evaluate the effects of psychological and PA-based interventions on PA, seizure activity, psychiatric comorbidity, and health-related quality of life (HRQoL) in PWE.
Main Methods:
- Systematic review following PRISMA guidelines.
- Searches conducted across PubMed, Cochrane, PsycINFO, and Embase databases.
- Inclusion of case-control, cross-sectional, and intervention studies using questionnaires, activity trackers, and fitness tests.
Main Results:
- Over half of case-control studies using self-report measures indicated lower PA in PWE.
- A majority of studies using fitness tests showed poorer performance in PWE.
- Positive associations found between PA and HRQoL/reduced depression/anxiety; PA interventions improved PA and HRQoL.
Conclusions:
- There is preliminary evidence suggesting PWE may have lower PA levels than controls.
- PA-based interventions appear beneficial for improving PA and HRQoL in PWE.
- Further high-quality research with robust designs is necessary to confirm these findings and understand PA in epilepsy.
More Related Videos
Related Concept Videos
Epilepsy and Seizures: Overview
1.0K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.0K
Seizures: Classification
1.2K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
Antiepileptic Drugs: Potassium Channel Activators
524
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
524
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
718
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
718

